Managers / Q1 2026
BOONE CAPITAL MANAGEMENT LLC
CIK 0001882053 · 1175 PEACHTREE ST NE, SUITE 1625, ATLANTA, GA, 30361 · 404-891-9290
Summary
Boone Capital Management LLC reported $326M in U.S.-listed holdings across 13 positions for Q1 2026.
Its largest position, MIRM, represents 11.9% of the portfolio.
Compared with Q4 2025, the fund opened 5 new positions and exited 7.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 82.8% · $270M
- Other · 17.2% · $56M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TFXTELEFLEX INCORPORATED | NEW | +278.8K | 278.8K | +$33M | $33M |
| GRDNGUARDIAN PHARMACY SVCS INC | NEW | +631.2K | 631.2K | +$24M | $24M |
| ASTRAZENECA PLC | NEW | +110.1K | 110.1K | +$22M | $22M |
| AVNSAVANOS MED INC | NEW | +1.18M | 1.18M | +$17M | $17M |
| TENXTENAX THERAPEUTICS INC | NEW | +200.0K | 200.0K | +$3M | $3M |
| NBIXNEUROCRINE BIOSCIENCES INC | SOLD OUT | −151.8K | 0 | −$22M | $0 |
| AZNNASTRAZENECA PLC | SOLD OUT | −220.2K | 0 | −$20M | $0 |
| HQYHEALTHEQUITY INC | SOLD OUT | −212.9K | 0 | −$19M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MIRMMIRUM PHARMACEUTICALS INChistory → | COM | 11.92% | $39M | 421.2K |
| 2 | ISIIONIS PHARMACEUTICALS INChistory → | COM | 11.51% | $38M | 500.5K |
| 3 | CITHE CIGNA GROUPhistory → | COM | 11.24% | $37M | 137.5K |
| 4 | MEDTRONIC PLC | SHS | 10.57% | $34M | 398.1K |
| 5 | TFXTELEFLEX INCORPORATEDhistory → | COM | 10.22% | $33M | 278.8K |
| 6 | BMRNBIOMARIN PHARMACEUTICAL INChistory → | COM | 9.48% | $31M | 547.9K |
| 7 | GRDNGUARDIAN PHARMACY SVCS INChistory → | CL A | 7.28% | $24M | 631.2K |
| 8 | ASTRAZENECA PLC | ORD | 6.65% | $22M | 110.1K |
| 9 | UNHUNITEDHEALTH GROUP INChistory → | COM | 6.57% | $21M | 79.2K |
| 10 | BBIOBRIDGEBIO PHARMA INChistory → | COM | 5.21% | $17M | 228.8K |
| 11 | AVNSAVANOS MED INChistory → | COM | 5.09% | $17M | 1.18M |
| 12 | KODKODIAK SCIENCES INChistory → | COM | 3.29% | $11M | 281.3K |
| 13 | TENXTENAX THERAPEUTICS INC | COM NEW | 0.98% | $3M | 200.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $326M | 13 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $319M | 15 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $305M | 16 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $233M | 11 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $294M | 12 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $296M | 13 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $386M | 17 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $383M | 19 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $494M | 21 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $428M | 21 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $317M | 13 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $279M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $214M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $195M | 17 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.